ANNOVIS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.82 USD | -9.91% |
|
-21.11% | -74.22% |
| 30/04 | Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating | MT |
| 29/04 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 51.96 | 142.4 | 109.6 | 191.9 | 53.07 | - | - |
| Enterprise Value (EV) 1 | 51.96 | 142.4 | 109.6 | 186.1 | -36.03 | 15.37 | -28.83 |
| P/E ratio | -8.67 x | -9.25 x | -4.33 x | -3 x | -1.75 x | -1.92 x | -2.26 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 6.47 x |
| EV / Revenue | - | - | - | - | - | - | -3.51 x |
| EV / EBITDA | - | - | - | -4.13 x | 0.96 x | -0.35 x | 0.45 x |
| EV / FCF | - | - | - | -4.66 x | 1.13 x | -0.3 x | 0.52 x |
| FCF Yield | - | - | - | -21.5% | 88.8% | -334% | 194% |
| Price to Book | - | - | - | -21.8 x | 1.46 x | 3.42 x | 1.77 x |
| Nbr of stocks (in thousands) | 6,892 | 8,101 | 8,164 | 10,262 | 11,011 | - | - |
| Reference price 2 | 7.540 | 17.58 | 13.43 | 18.70 | 4.820 | 4.820 | 4.820 |
| Announcement Date | 03/03/21 | 02/03/22 | 31/03/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 8.209 |
| EBITDA 1 | - | - | - | -45.04 | -37.4 | -44 | -64 |
| EBIT 1 | - | -14.54 | -25.51 | -45.04 | -40.46 | -51.13 | -60.01 |
| Operating Margin | - | - | - | - | - | - | -731.08% |
| Earnings before Tax (EBT) 1 | - | -14.49 | -25.33 | -56.2 | -39.68 | -54.94 | -77.96 |
| Net income 1 | -5.462 | -14.49 | -25.33 | -56.2 | -39.68 | -54.94 | -77.96 |
| Net margin | - | - | - | - | - | - | -949.67% |
| EPS 2 | -0.8700 | -1.900 | -3.100 | -6.230 | -2.754 | -2.505 | -2.133 |
| Free Cash Flow 1 | - | - | - | -39.97 | -32 | -51.4 | -55.8 |
| FCF margin | - | - | - | - | - | - | -679.74% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 03/03/21 | 02/03/22 | 31/03/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -10.44 | -6.4 | -6.7 | -11.9 | -12.4 | - |
| EBIT 1 | -2.854 | -5.92 | -5.914 | -8.754 | -7.674 | -3.169 | -9.97 | -9.76 | -14.86 | -10.44 | -8.655 | -8.271 | -9.863 | -9.898 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.848 | -5.915 | -5.894 | -8.718 | -7.621 | -3.095 | -9.737 | -9.537 | -14.72 | -22.21 | -9.092 | -8.474 | -9.507 | -9.558 | - |
| Net income 1 | -2.848 | -5.915 | -5.894 | -8.7 | -7.621 | -3.095 | -9.737 | -9.537 | -14.72 | -22.21 | -9.092 | -8.474 | -9.507 | -9.558 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3500 | -0.7500 | -0.7200 | -1.070 | -0.9300 | -0.3800 | -1.190 | -1.070 | -1.630 | -2.330 | -0.8375 | -0.6250 | -0.6025 | -0.5925 | -0.4800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 03/11/21 | 02/03/22 | 04/05/22 | 08/08/22 | 08/11/22 | 31/03/23 | 10/05/23 | 14/08/23 | 08/11/23 | 29/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 5.75 | 89.1 | 37.7 | 81.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -40 | -32 | -51.4 | -55.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | -110% | -77.8% | -105% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | -0.8600 | 3.300 | 1.410 | 2.720 |
| Cash Flow per Share 2 | - | - | - | -4.430 | -1.350 | -1.780 | -1.730 |
| Capex 1 | - | - | - | - | 1 | 2 | 2 |
| Capex / Sales | - | - | - | - | - | - | 24.36% |
| Announcement Date | 03/03/21 | 02/03/22 | 31/03/23 | 29/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
4.82
USD
Average target price
33.4
USD
Spread / Average Target
+592.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -74.22% | 58.91M | |
| +2.93% | 106B | |
| +7.02% | 23.47B | |
| -14.60% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.83% | 16.78B | |
| +5.51% | 14.41B | |
| +37.49% | 12.86B | |
| +329.39% | 8.78B |
- Stock Market
- Equities
- ANVS Stock
- Financials Annovis Bio, Inc.